相关实验视频

Updated: Jan 7, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

理性设计和结构生物信息学-为LIMK向癌症治疗而发现四甲抑制剂-向癌症治疗

Nagarajan Hemavathy¹, Sampathkumar Ranganathan², Vetrivel Umashankar³

¹Structural Biology and Bio-Computing Lab, Department of Bioinformatics, Science Block, Alagappa University, Karaikudi, 630 003, Tamil Nadu, India.

Medical oncology (Northwood, London, England)

|December 26, 2025

概括

研究人员确定了新型四甲,WRHF,YYRW和WWHW,作为LIM激酶 (LIMK1和LIMK2) 的潜在选择性抑制剂. 这些基于的药物显示出开发针对微管子动态的较少毒性癌症疗法的前景.

科学领域:

结构生物信息学和计算药物发现.
分子生物学和癌症治疗学.

背景情况:

LIM激酶 (LIMK1和LIMK2) 对微管动力学和细胞分裂至关重要,使它们成为有吸引力的癌症标.
现有的LIMK抑制剂缺乏特异性,导致由于保留的蛋白质结构导致毒性.
尚未探索针对LIMK ATP结合口袋的基抑制剂.

研究的目的:

使用计算方法识别LIM激酶的选择性和较少毒性抑制剂.
发现用于LIMK向癌症治疗的新疗法,减少非向效应.

主要方法:

综合性结构生物信息学方法,包括对寡类库的虚拟选.
分子动力学模拟 (MDS) 和结合自由能量分析,以评估抑制剂-标相互作用.
优先考虑具有已知的抗癌,抗炎和抗血管原性质的.

主要成果:

鉴定出四个和五个模仿已知抑制剂与LIMK1和LIMK2相互作用的四甲.
WRHF显示出强大的LIMK1抑制,比参考抑制剂LIMKi3.3具有更高的亲和力.
对于LIMK2抑制,YYRW和WWHW显示出优越的稳定性和结合强度.

结论:

WRHF (LIMK1),YYRW和WWHW (LIMK2) 是稳定的,具有治疗潜力的高亲和度四甲抑制剂.
这些体代表了开发有选择性,低毒性癌症治疗药物的有希望的候选人,其向的目标是LIM激酶.
进一步的体外和体内验证是必要的,以确认疗效和治疗潜力.

关键词:

结合能量是有约束力的.有限公司LIMKs 分子动力学分子动力学类抑制剂类抑制剂虚拟选是一个虚拟的选.

更多相关视频

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Published on: July 25, 2013

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...